Serotonin

Kuhnil Pharmaceutical launched Slenyto SR Tablet, a melatonin-based insomnia treatment for children and adolescents with Autism Spectrum Disorders (ASD) and Smith-Magenis syndrome (SMS). Slenyto, developed by Neurim Pharmaceuticals, showed significant improvements in sleep duration and maintenance, with no significant adverse effects. The treatment also enhanced caregivers' quality of life.

NIH lab mimics bar to study if anti-obesity drugs curb alcohol cravings; evidence suggests GLP-1 receptor agonists may reduce various addictions. Clinical trials underway, with potential benefits beyond weight loss, including reducing cardiovascular risks, easing sleep apnoea, and slowing Parkinson’s development. Understanding drug mechanisms could optimize responses and mitigate side effects.

A study by the University of Oxford found triptans, particularly eletriptan, rizatriptan, sumatriptan, and zolmitriptan, to be the most effective for acute migraine relief, with efficacy comparable to paracetamol. Triptans, underused and effective, should be considered a preferred treatment, according to lead author Andrea Cipriani.

Autobahn Therapeutics starts AMPLIFY Phase 2 trial for ABX-002, targeting major depressive disorder (MDD) with a 230-patient study. ABX-002, a TRβ agonist, showed safety and efficacy in Phase 1. Topline data expected by late 2025, with a bipolar disorder trial planned for late 2024.

Tilray advances in Europe with new cannabis licenses in Germany and product approvals in Portugal. Glass House Brands wins a lawsuit dismissal. GrowGeneration reports revenue growth despite store closures. Awakn updates on its psychedelic compound patents. Compass Pathways receives a positive rating from RBC for its psychedelic treatment research.

Tracey Tee founded Moms on Mushrooms, a platform for mothers to share experiences with microdosing psilocybin mushrooms, after personal health challenges and the pandemic led her to explore psychedelics. The group aims to foster healing and community among mothers, emphasizing safety and intention in microdosing practices.

ConSynance Therapeutics receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome, aiming to address hyperphagia and severe temper outbursts through a Triple Monoamine Reuptake Inhibitor.

Psychedelics, studied since the 1890s, showed potential in psychiatric treatment, especially post-LSD synthesis in 1938. Despite 1960s-70s prohibition, their therapeutic use, emphasizing 'set and setting', has revived since 2006, with modern research exploring their efficacy in treating severe psychiatric conditions, highlighting the need for psychological care and integration in treatment protocols.

The gut significantly impacts overall health, influencing heart disease, diabetes, and autoimmune conditions. A healthy gut microbiome, fostered by diet, exercise, and sleep, can prevent illnesses. Gut inflammation affects the whole body, and the gut-brain axis influences digestion, pain, and mood. Managing stress, diet, and lifestyle can improve gut health and alleviate conditions like IBS.